Connect Biopharma Holdings Ltd
CNTB1.680USD
+0.030+1.82%
收盤 11/04, 16:00（美東）報價延遲15分鐘
93.37M總市值
虧損本益比TTM
關於 Connect Biopharma Holdings Ltd 公司
Connect Biopharma Holdings Limited 是一家全球臨牀階段生物製藥公司，專注於通過開發源自 T 細胞驅動研究的療法來改善慢性炎症疾病患者的生活。該公司正在建立專有小分子和抗體產品線，使用功能性 T 細胞檢測來篩選和發現針對經過驗證的免疫靶點的有效候選產品。其主要候選產品 rademikibart 是一種針對白細胞介素 4 受體 α (IL-4Rα) 的抗體，正在開發用於治療特應性皮炎 (AD) 和哮喘。作爲 IL-4Rα 的抑制劑，rademikibart 可阻斷 IL-4 和 IL-13 的炎症信號傳導。其第二個候選產品 icanbelimod 是 S1P1 T 細胞受體的調節劑，正在開發用於治療潰瘍性結腸炎 (UC)。Icanbelimod 是一種口服的 S1P1 小分子調節劑，旨在減少炎症而不殺死 T 細胞。
Connect Biopharma Holdings Ltd簡介
公司代碼CNTB
公司名稱Connect Biopharma Holdings Ltd
上市日期Mar 19, 2021
CEODr. Barry D. Quart, Pharm.D.
員工數量62
證券類型Ordinary Share
年結日Mar 19
公司地址3580 Carmel Mountain Road, Suite 200
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編92130
電話18587271040
網址https://www.connectbiopharm.com
公司代碼CNTB
上市日期Mar 19, 2021
CEODr. Barry D. Quart, Pharm.D.
Connect Biopharma Holdings Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
131.89K
--
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
80.00K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
--
--
Kimberly Kimberly
Kimberly Kimberly
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Dr. Lei Sun, Ph.D.
Dr. Lei Sun, Ph.D.
Vice President - Biologics and Head of CMC
Vice President - Biologics and Head of CMC
--
--
Mr. Jeff Cohn, J.D.
Mr. Jeff Cohn, J.D.
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
--
--
Mr. Raul Collazo, Ph.D.
Mr. Raul Collazo, Ph.D.
Vice President - Global Medical Affairs
Vice President - Global Medical Affairs
--
--
Mr. David L. Szekeres
Mr. David L. Szekeres
President
President
--
--
Dr. Kan Chen, Ph.D.
Dr. Kan Chen, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
131.89K
--
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
80.00K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
--
--
Kimberly Kimberly
Kimberly Kimberly
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Dr. Lei Sun, Ph.D.
Dr. Lei Sun, Ph.D.
Vice President - Biologics and Head of CMC
Vice President - Biologics and Head of CMC
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Panacea Venture
25.04%
BioFortune Inc
11.05%
Wei (Zheng)
10.64%
Shanghai Minhui Enterprise Management Consulting Partnership
9.52%
Qiming Venture Partners
8.69%
其他
35.06%
持股股東
持股股東
佔比
Panacea Venture
25.04%
BioFortune Inc
11.05%
Wei (Zheng)
10.64%
Shanghai Minhui Enterprise Management Consulting Partnership
9.52%
Qiming Venture Partners
8.69%
其他
35.06%
股東類型
持股股東
佔比
Venture Capital
39.76%
Corporation
29.12%
Individual Investor
11.41%
Investment Advisor
4.01%
Hedge Fund
0.39%
Investment Advisor/Hedge Fund
0.04%
其他
15.26%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
40
24.63M
44.21%
-4.35M
2025Q2
50
47.05M
84.81%
-3.22M
2025Q1
52
47.02M
84.62%
-3.27M
2024Q4
55
47.53M
86.01%
-3.17M
2024Q3
62
47.29M
85.59%
-4.20M
2024Q2
69
47.32M
85.65%
-6.58M
2024Q1
72
46.88M
84.93%
-2.00M
2023Q4
79
44.04M
79.91%
+3.48M
2023Q3
88
43.03M
78.17%
-1.22M
2023Q2
89
43.32M
78.69%
-1.54M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Panacea Venture
13.95M
25.04%
+540.00K
+4.03%
Jul 21, 2025
BioFortune Inc
6.16M
11.05%
--
--
Mar 21, 2025
Wei (Zheng)
5.93M
10.64%
--
--
Mar 21, 2025
Shanghai Minhui Enterprise Management Consulting Partnership
5.31M
9.52%
--
--
Mar 21, 2025
Qiming Venture Partners
4.84M
8.69%
--
--
Mar 21, 2025
Advantech Capital II L.P.
4.76M
8.55%
--
--
Mar 21, 2025
Lilly Asia Ventures
3.34M
5.99%
--
--
Mar 21, 2025
BML Capital Management LLC
1.82M
3.27%
-271.67K
-12.98%
Jun 30, 2025
Szekeres (David Leslie)
160.87K
0.29%
+160.87K
--
Mar 21, 2025
Choreo, LLC
160.87K
0.29%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
SPDR Portfolio Emerging Markets ETF
0%
SPDR Portfolio Emerging Markets ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
